IL304567B1 - שיטה לזיהוי pik3ca אונקוגני - Google Patents
שיטה לזיהוי pik3ca אונקוגניInfo
- Publication number
- IL304567B1 IL304567B1 IL304567A IL30456723A IL304567B1 IL 304567 B1 IL304567 B1 IL 304567B1 IL 304567 A IL304567 A IL 304567A IL 30456723 A IL30456723 A IL 30456723A IL 304567 B1 IL304567 B1 IL 304567B1
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- nucleic acid
- acid molecule
- cytosine
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL304567A IL304567B2 (he) | 2023-07-18 | 2023-07-18 | שיטה לזיהוי pik3ca אונקוגני |
| PCT/IL2024/050707 WO2025017560A1 (en) | 2023-07-18 | 2024-07-18 | Methods of detecting oncogenic pik3ca |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL304567A IL304567B2 (he) | 2023-07-18 | 2023-07-18 | שיטה לזיהוי pik3ca אונקוגני |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL304567A IL304567A (he) | 2023-08-01 |
| IL304567B1 true IL304567B1 (he) | 2024-03-01 |
| IL304567B2 IL304567B2 (he) | 2024-07-01 |
Family
ID=90097898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL304567A IL304567B2 (he) | 2023-07-18 | 2023-07-18 | שיטה לזיהוי pik3ca אונקוגני |
Country Status (2)
| Country | Link |
|---|---|
| IL (1) | IL304567B2 (he) |
| WO (1) | WO2025017560A1 (he) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150079076A1 (en) * | 2011-12-09 | 2015-03-19 | Roche Molecular Systems | Identification of non-responders to her2 inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201726140A (zh) * | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
-
2023
- 2023-07-18 IL IL304567A patent/IL304567B2/he unknown
-
2024
- 2024-07-18 WO PCT/IL2024/050707 patent/WO2025017560A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150079076A1 (en) * | 2011-12-09 | 2015-03-19 | Roche Molecular Systems | Identification of non-responders to her2 inhibitors |
Non-Patent Citations (4)
| Title |
|---|
| ENSEMBL GENOME DATABASE PROJECT, TRANSCRIPT: ENST00000263967.4 PIK3CA-201., 17 July 2023 (2023-07-17) * |
| MADSEN, R. R., CANCER-ASSOCIATED PIK3CA MUTATIONS IN OVERGROWTH DISORDERS., 24 October 2018 (2018-10-24) * |
| TAHER, M. M., SUPRATENTORIAL SPORADIC HEMANGIOBLASTOMA: A CASE REPORT WITH MUTATION PROFILING USING NEXT-GENERATION DNA SEQUENCING., 1 June 2023 (2023-06-01) * |
| ZHANG, H. ET AL., PATIENT-DERIVED XENOGRAFTS OF TRIPLE-NEGATIVE BREAST CANCER REPRODUCE MOLECULAR FEATURES OF PATIENT TUMORS AND RESPOND TO MTOR INHIBITION., 7 April 2014 (2014-04-07) * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL304567B2 (he) | 2024-07-01 |
| WO2025017560A1 (en) | 2025-01-23 |
| IL304567A (he) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ghaemmaghami et al. | Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis | |
| Wang et al. | Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes | |
| JP2026062949A (ja) | メラノーマの処置および診断 | |
| Metro et al. | Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype | |
| Klekner et al. | Significance of liquid biopsy in glioblastoma–A review | |
| US9187787B2 (en) | Method of diagnosing and treating cancer | |
| Zhou et al. | Overexpression of lncRNA TUG1 alleviates NLRP3 inflammasome-mediated cardiomyocyte pyroptosis through targeting the miR-186-5p/XIAP axis in coronary microembolization-induced myocardial damage | |
| Bernier-Latmani et al. | Apelin-driven endothelial cell migration sustains intestinal progenitor cells and tumor growth | |
| Feng et al. | MicroRNA-155 regulates T cell proliferation through targeting GSK3β in cardiac allograft rejection in a murine transplantation model | |
| WO2014071067A2 (en) | Treatment and diagnosis of colon cancer | |
| CN114634984A (zh) | 一种脑胶质瘤生物标记物mlkl基因及其应用 | |
| Li et al. | Cardiac Injury Regulates Neuroinflammation Through Extracellular Vesicle–Mediated Heart-Brain Crosstalk | |
| Chen et al. | The utility of cerebrospinal fluid–derived cell-free DNA in molecular diagnostics for the PIK3CA-related megalencephaly-capillary malformation (MCAP) syndrome: a case report | |
| CN120060476A (zh) | 一种前列腺癌奥拉帕利治疗耐药标志物及其应用 | |
| Mu et al. | Exosomal miR-1228-5p down-regulates DUSP22 to promotes cell proliferation and migration in small cell lung cancer | |
| Shen et al. | Exosomes secreted by metastatic cancer cells promotes epithelial mesenchymal transition in small cell lung carcinoma: the key role of Src/TGF-β1 axis | |
| CN108025017A (zh) | MiR-19调节剂及其用途 | |
| Chen et al. | Ribosomal protein L36-mediated selective loading of microRNA-4432 into extracellular vesicles contributes to perivascular cell dysfunction in venous malformations | |
| IL304567B2 (he) | שיטה לזיהוי pik3ca אונקוגני | |
| US20080318241A1 (en) | Methods and Systems for Detecting Antiangiogenesis | |
| Hussein et al. | NEAT1: Culprit lncRNA linking PIG-C, MSLN, and CD80 in triple-negative breast cancer | |
| CN114107492B (zh) | 一种用于肿瘤分子分型、治疗用药评估的分子标志物及其检测引物和试剂盒 | |
| JP2024502001A (ja) | ラブドイド腫瘍を治療する方法 | |
| Deng et al. | Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer | |
| CA3202058A1 (en) | A jmjd6 targeting agent for treating prostate cancer |